Bellomo, Giovanni

Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid

Gobom, J., Parnetti, L., Rosa-Neto, P., Vyhnalek, M., Gauthier, S., Cataldi, S., Lerch, O., Laczo, J., Cechova, K., Clarin, M., et al. (2022) · Clinical Chemistry and Laboratory Medicine (CCLM)

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 146

An Unbalanced Synaptic Transmission: Cause or Consequence of the Amyloid Oligomers Neurotoxicity?

Sciaccaluga, M., Megaro, A., Bellomo, G., Ruffolo, G., Romoli, M., Palma, E., & Costa, C. (2021) · International Journal of Molecular Sciences

Alzheimer's disease research and treatmentsNeuroscience and Neuropharmacology Research

Cited by 70

Trajectories of CSF and plasma biomarkers across Alzheimer's disease continuum: disease staging by NF-L, p-tau181, and GFAP

Wojdała, A. L., Bellomo, G., Gaetani, L., Toja, A., Chipi, E., Shan, D., Chiasserini, D., & Parnetti, L. (2023) · Neurobiology of Disease

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 70

A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias

Bolsewig, K., Hok-A-Hin, Y. S., Sepe, F. N., Boonkamp, L., Jacobs, D., Bellomo, G., Paoletti, F. P., Vanmechelen, E., Teunissen, C. E., Parnetti, L., et al. (2022) · Journal of Alzheimer's Disease

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 36

Status of the high energy SC linac for the TRASCO program

Pagani, C., Barni, D., Bellomo, G., Bosotti, A., Michelato, P., Paulon, R., Pierini, P., Sertore, D., & Varisco, G. (2002) · PACS2001. Proceedings of the 2001 Particle Accelerator Conference (Cat. No.01CH37268)

Particle accelerators and beam dynamicsSuperconducting Materials and Applications

Cited by 6